Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Moving towards the pan-European unification of Multiple Sclerosis Nurses: a consensus paper.
Transverse myelitis associated with heroin and cannabis abuse: a new issue from the past.
Genome-wide association study of multiple sclerosis confirms a novel locus at 5p13.1.
A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - A twelve month follow-up.
[Cognitive impairment in demyelinating disease].
Successful desensitization to natalizumab in a skin test--positive patient: a case report.
Review of MR elastography applications and recent developments.
[Pharmacological properties and clinical efficacy of fingolimod hydrochloride (Imusera®/Gilenya®) for the treatment of multiple sclerosis].
Receptos begins enrollment of Phase 3 trial of RPC1063 in relapsing multiple sclerosis
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis.
Identification of protein networks involved in the disease course of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis.
Optic nerve disease and axon pathophysiology.
Confronting the diagnosis of multiple sclerosis: a qualitative study of patient experiences.
Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis.
Age-dependent effects on the treatment response of natalizumab in MS patients.
Embryonic stem cell lines derived from human blastocysts.
The "liberation procedure" for multiple sclerosis: sacrificing science at the altar of consumer demand.
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial.
Optic neuritis in a child with biotinidase deficiency: case report and literature review.
Autoinflammatory grey matter lesions in humans: cortical encephalitis, clinical disorders, experimental models.
A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta.
Huperzine A ameliorates experimental autoimmune encephalomyelitis via the suppression of T cell-mediated neuronal inflammation in mice.
CHMP recommends granting a marketing authorization for Santhera's Raxone® for the treatment of Leber's Hereditary Optic Neuropathy (LHON)
Emerging tumefactive MS after switching therapy from interferon-beta to fingolimod: A case report.
Physical activity and associated levels of disability and quality of life in people with multiple sclerosis: a large international survey.

Pages